Skip to main content

Table 2 CumAIP-associated T2D risks in the entire cohort and across the cumulative CRP thresholds (1, 3 mg/L)

From: Temporal relationship between atherogenic dyslipidemia and inflammation and their joint cumulative effect on type 2 diabetes onset: a longitudinal cohort study

 

CumAIP, HRs (95% CIs)

Per SDa

P for trend

Quartile1

Quartile 2

Quartile 3

Quartile 4

Entire cohort

 Event/total

684/10, 840

1023/10, 840

1395/10, 840

2016/10, 840

  

 Incident rate

8.6

13.37

18.6

27.32

  

 Model 1

Reference

1.37 (1.24, 1.51)

1.76 (1.60, 1.93)

2.40 (2.20, 2.63)

1.36 (1.32, 1.39)

< 0.0001

 Model 2

Reference

1.26 (1.14, 1.39)

1.55 (1.41, 1.70)

2.03 (1.85, 2.22)

1.28 (1.24, 1.31)

< 0.0001

 Model 3

Reference

1.23 (1.11, 1.35)

1.44 (1.31, 1.58)

1.75 (1.60, 1.92)

1.20 (1.17, 1.24)

< 0.0001

CumCRP < 1 mg/L

 Event/total

191/4462

238/3624

321/3287

388/2638

  

 Incident rate

5.76

9.2

13.88

21.35

  

 Model 1

Reference

1.38 (1.14, 1.67)

1.92 (1.59, 2.30)

2.78 (2.31, 3.33)

1.47 (1.39, 1.56)

< 0.0001

 Model 2

Reference

1.27 (1.05, 1.54)

1.59 (1.32, 1.91)

2.28 (1.90, 2.75)

1.36 (1, 29, 1.45)

< 0.0001

 Model 3

Reference

1.24 (1.02, 1.50)

1.48 (1.23, 1.79)

1.99 (1.65, 2.40)

1.28 (1.20, 1.36)

< 0.0001

1 ≤ CumCRP < 3 mg/L

 Event/total

304/3952

485/4633

658/4932

954/5034

  

 Incident rate

10.55

14.83

19.31

27.85

  

 Model 1

Reference

1.26 (1.10, 1.46)

1.55 (1.35, 1.77)

2.13 (1.86, 2.44)

1.31 (1.26, 1.37)

< 0.0001

 Model 2

Reference

1.15 (0.99, 1.32)

1.37 (1.20, 1.58)

1.81 (1.58, 2.07)

1.25 (1.20, 2.30)

< 0.0001

 Model 3

Reference

1.14 (0.98, 1.31)

1.31 (1.14, 1.50)

1.62 (1.41, 1.85)

1.19 (1.14, 1.24)

< 0.0001

CumCRP ≥ 3 mg/L

 Event/total

189/2426

300/2583

416/2621

674/3168

  

 Incident rate

10.79

16.74

23.38

31.55

  

 Model 1

Reference

1.41 (1.18, 1.70)

1.84 (1.54, 2.18)

2.31 (1.96, 2.73)

1.30 (1.24, 1.36)

< 0.0001

 Model 2

Reference

1.34 (1.12, 1.61)

1.68 (1.41, 2.01)

2.00 (1.69, 2.37)

1.23 (1.17, 1.29)

< 0.0001

 Model 3

Reference

1.30 (1.08, 1.56)

1.58 (1.32, 1.88)

1.73 (1.46, 2.06)

1.16 (1.10, 1.22)

< 0.0001

P for INTm: CumAIP quartile × CumCRP thresholds (1, 3 mg/L) = 0.0308; CumAIP quartiles × logCumCRP = 0.0286

  1. Quartile 1: CumAIP < − 0.2387; quartile 2: − 0.2387 ≤ CumAIP < − 0.0701; quartile 3: − 0.0701 ≤ CumAIP < 0.0989; quartile 4: CumAIP > 0.0989
  2. Model 1: adjusted for baseline age, sex, education, smoking, drinking status, physical activities, family history of diabetes, BMI; model 2: model 1 + FBG, TC, blood pressure (categorical), eGFR (categorical), antihypertensives, lipid-lowering drugs, logBasCRP (continuous, only in the entire cohort); model 3: model 2 + fatty liver (categorical)
  3. Abbreviations: CumAIP, cumulative atherogenic index of plasma; CumCRP, cumulative high-sensitivity C-reactive protein; BMI, body mass index; FBG, fasting blood glucose; TC, total cholesterol; eGFR, estimated glomerular filtration rate; BasCRP: baseline high-sensitivity C-reactive protein; INTm, multiplicative interaction
  4. aPer SD, hazard ratio for per SD (0.2658) change in CumAIP